Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Fluvoxamine  COVID-19 treatment studies for Fluvoxamine  C19 studies: Fluvoxamine  Fluvoxamine   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Case, SSRI 43% Improvement Relative Risk Case, All 39% c19early.org/f Glebov et al. Fluvoxamine for COVID-19 Prophylaxis Favors fluvoxamine Favors control
Antidepressant drug prescription and incidence of COVID-19: a retrospective cohort study
Glebov et al., medRxiv, doi:10.1101/2022.12.15.22283507 (Preprint)
Glebov et al., Antidepressant drug prescription and incidence of COVID-19: a retrospective cohort study, medRxiv, doi:10.1101/2022.12.15.22283507 (Preprint)
Dec 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 5,664 mental health patients in the UK, showing lower risk of COVID-19 cases with recent antidepressant prescriptions overall, and for the subset of patients receiving SSRIs.
risk of case, 43.0% lower, OR 0.57, p = 0.04, adjusted per study, 90 days, SSRI, RR approximated with OR.
risk of case, 39.0% lower, OR 0.61, p = 0.03, adjusted per study, 90 days, all antidepressants, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Glebov et al., 20 Dec 2022, retrospective, United Kingdom, preprint, 5 authors, study period 1 April, 2020 - 31 December, 2020.
Contact: oleg.glebov@kcl.ac.uk.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFluvoxamineAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2022.12.15.22283507; this version posted December 20, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Antidepressant drug prescription and incidence of COVID-19: a retrospective cohort study Oleg O. Glebov1,2* Ph.D., Christoph Mueller2,3 M.D., Robert Stewart2,3 M.D., Dag Aarsland2,4 M.D., Gayan Perera2 Ph.D. 1 Institute of Neuroregeneration and Neurorehabilitation, Department Pathophysiology, School of Basic Medicine, Qingdao University, Shandong, China. of 2 Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK. 3 South London and Maudsley NHS Foundation Trust, London, UK. 4 Centre for Age-related research, Stavanger University Hospital, Stavanger, Norway. * contact e-mail: oleg.glebov@kcl.ac.uk Word count: 1292 (Main Text) Key points Question Is there an association between prescription of antidepressants and incidence of COVID-19 in the general population? Findings In this retrospective cohort study of mental health outpatients with a recent (1-3 months) antidepressant prescription, there was a statistically significant 40% decrease in positive COVID-19 tests. This association was specifically observed for the most commonly prescribed antidepressant class, Selective Serotonin Reuptake Inhibitors, and remained when adjusted for socioeconomic parameters and physical health. Meaning Antidepressant prescription was associated with lower incidence of COVID-19 in the community, warranting further investigation as prophylactics in prospective clinical studies. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2022.12.15.22283507; this version posted December 20, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Abstract While antidepressant drugs (ADs) have shown some efficacy in treatment of COVID-19, their preventative potential remains unexplored. To investigate association between AD and COVID-19 incidence in the community, we analysed data from community-living, nonhospitalized adults admitted to inpatient care of the South London&Maudsley (SLaM) NHS Foundation Trust during the 1st wave of COVID-19 pandemic in the UK. Prescription of ADs within the period of 1 to 3 months before admission was associated with an approximately 40% decrease in positive COVID-19 test results when adjusted for socioeconomic parameters and physical health. This association was specifically observed for ADs of the Selective Serotonin Reuptake Inhibitor (SSRI) class. These results suggest that ADs, specifically SSRIs, may help prevent COVID-19 infection in the community. Definitive determination of AD preventative potential warrants prospective studies in the wider general population. Main text More than 2.5 years since the declaration of the global COVID-19 pandemic, it remains a major public health burden across the world, with further waves of infection more likely than not. To this day, the only available method for prevention of..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit